BRPI0911988A2 - micelas para liberação intracelular de agentes terapêuticos. - Google Patents

micelas para liberação intracelular de agentes terapêuticos.

Info

Publication number: BRPI0911988A2
Authority: BR; Brazil
Prior art keywords: micelles; therapeutic agents; intracellular release; intracellular; release
Prior art date: 2008-05-13

Application number

BRPI0911988A

Other languages

English (en)

Inventor

Anthony J Convertine

Allan S Hoffman

Amber Paschal

Anna Gall

Charbel Diab

Mary Prieve

Patrick S Stayton

Paul Johnson

Priyadarsl De

Robert Overell

Original Assignee

Phaserx Inc

Univ Washington

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-13

Filing date

2009-05-13

Publication date

2015-10-13

2009-05-13 Application filed by Phaserx Inc, Univ Washington filed Critical Phaserx Inc

2015-10-13 Publication of BRPI0911988A2 publication Critical patent/BRPI0911988A2/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
- C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2438/00—Living radical polymerisation
- C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Organic Chemistry (AREA)
Dispersion Chemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Nanotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
Polymers & Plastics (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0911988A 2008-05-13 2009-05-13 micelas para liberação intracelular de agentes terapêuticos. BRPI0911988A2 (pt)

Applications Claiming Priority (10)

Application Number	Priority Date	Filing Date	Title
US5291408P	2008-05-13	2008-05-13
US5290808P	2008-05-13	2008-05-13
US9129408P	2008-08-22	2008-08-22
US11204808P	2008-11-06	2008-11-06
US11205408P	2008-11-06	2008-11-06
US14077408P	2008-12-24	2008-12-24
US14077908P	2008-12-24	2008-12-24
US17135809P	2009-04-21	2009-04-21
US17136909P	2009-04-21	2009-04-21
PCT/US2009/043853 WO2009140432A2 (en)	2008-05-13	2009-05-13	Micelles for intracellular delivery of therapeutic agents

Publications (1)

Publication Number	Publication Date
BRPI0911988A2 true BRPI0911988A2 (pt)	2015-10-13

Family

ID=41319325

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0911988A BRPI0911988A2 (pt)	2008-05-13	2009-05-13	micelas para liberação intracelular de agentes terapêuticos.

Country Status (12)

Country	Link
US (1)	US20110142951A1 (pt)
EP (1)	EP2296627A2 (pt)
JP (1)	JP2011520901A (pt)
KR (1)	KR20110020804A (pt)
CN (1)	CN102076328A (pt)
AU (1)	AU2009246332A1 (pt)
BR (1)	BRPI0911988A2 (pt)
CA (1)	CA2724472A1 (pt)
IL (1)	IL209236A0 (pt)
MX (1)	MX2010012237A (pt)
WO (1)	WO2009140432A2 (pt)
ZA (1)	ZA201008732B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009140421A2 (en)	2008-05-13	2009-11-19	University Of Washington	Polymeric carrier
CA2724014C (en)	2008-05-13	2016-09-13	University Of Washington	Micellic assemblies
MX2010012238A (es)	2008-05-13	2011-04-11	Univ Washington	Copolimeros dibloque y sus complejos con polinucleotidos destinados a introducirlos en celulas.
BRPI0913571A2 (pt)	2008-06-07	2015-10-20	James Hoffman	sistema de coleta de energia solar
CA2734917A1 (en)	2008-08-22	2010-02-25	University Of Washington	Heterogeneous polymeric micelles for intracellular delivery
EP2352522A4 (en)	2008-11-06	2014-03-05	Univ Washington	BISPECIFIC AUXILIARIES FOR INTRA-CELLULAR RELEASE
EP2364330B1 (en)	2008-11-06	2015-03-25	University Of Washington	Multiblock copolymers
CA2745926A1 (en)	2008-12-08	2010-07-08	Phaserx, Inc.	Omega-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization
US9080933B2 (en)	2009-11-09	2015-07-14	University Of Washington Through Its Center For Commercialization	Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates
WO2011060281A1 (en) *	2009-11-13	2011-05-19	University Of Washington Through Its Center For Commercialization	Hydrophobic block conjugated therapeutic agents
WO2011062965A2 (en)	2009-11-18	2011-05-26	University Of Washington Through Its Center For Commercialization	Targeting monomers and polymers having targeting blocks
US8349308B2 (en)	2010-03-26	2013-01-08	Mersana Therapeutics, Inc.	Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
MX2014001965A (es) *	2012-04-18	2014-03-31	Arrowhead Res Corp	Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
JP6195171B2 (ja)	2012-04-27	2017-09-13	国立大学法人東京大学	核酸デリバリー用ユニット構造型医薬組成物
AU2014296278C1 (en)	2013-07-30	2023-02-02	Genevant Sciences Gmbh	Block copolymers and their conjugates or complexes with oligonucleotides
PL405241A1 (pl)	2013-09-04	2015-03-16	Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością	Micela polimerowa, sposób jej wytwarzania i zastosowanie
WO2015088990A1 (en) *	2013-12-09	2015-06-18	Durect Corporation	Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
WO2015144886A1 (de) *	2014-03-27	2015-10-01	Sika Technology Ag	Blockcopolymer
US10709791B2 (en) *	2014-11-12	2020-07-14	University Of Washington	Stabilized polymeric carriers for therapeutic agent delivery
EP3247328B1 (en)	2015-01-21	2026-01-07	Genevant Sciences Gmbh	Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
KR20180085761A (ko) *	2015-11-20	2018-07-27	크리스탈 딜리버리 비.브이.	능동 타겟팅 나노입자
WO2017105138A1 (ko) *	2015-12-18	2017-06-22	주식회사 삼양바이오팜	음이온성 약물을 함유하는 고분자 미셀의 제조방법
WO2018045317A1 (en)	2016-09-02	2018-03-08	Dicerna Pharmaceuticals, Inc.	4'-phosphate analogs and oligonucleotides comprising the same
WO2018126084A1 (en)	2016-12-30	2018-07-05	Phaserx, Inc.	Branched peg molecules and related compositions and methods
EP3677268A4 (en)	2017-08-31	2021-04-21	The University Of Tokyo	UNIFORM POLYIONAL COMPLEX LOADED WITH NUCLEIC ACID
CN111344397A (zh) *	2017-11-01	2020-06-26	默沙东公司	巨细胞病毒的稳定制剂
CN108066285B (zh) *	2017-11-30	2019-06-07	江南大学	一种肝靶向共输送基因/药物的整合纳米系统及制备方法
CN111712468A (zh)	2017-12-22	2020-09-25	北卡罗莱纳州立大学	聚合物荧光团、包含其的组合物及制备和使用其的方法
WO2020205473A1 (en)	2019-03-29	2020-10-08	Decerna Pharmaceuticals, Inc.	Compositions and methods for the treatment of kras associated diseases or disorders
WO2020226960A1 (en)	2019-05-03	2020-11-12	Dicerna Pharmaceuticals, Inc.	Double-stranded nucleic acid inhibitor molecules with shortened sense strands
TW202140043A (zh)	2020-01-15	2021-11-01	美商戴瑟納製藥股份有限公司	4’-o-亞甲基膦酸酯核酸及其類似物
JP2023537499A (ja)	2020-08-04	2023-09-01	ディセルナファーマシューティカルズインコーポレイテッド	オリゴヌクレオチドの全身送達
CN113633613B (zh) *	2021-07-20	2023-04-25	河南大学	一种siRNA胶束、制备方法、组合物及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6359054B1 (en) *	1994-11-18	2002-03-19	Supratek Pharma Inc.	Polynucleotide compositions for intramuscular administration
US6410057B1 (en) *	1997-12-12	2002-06-25	Samyang Corporation	Biodegradable mixed polymeric micelles for drug delivery
US6383811B2 (en) *	1997-12-30	2002-05-07	Mirus Corporation	Polyampholytes for delivering polyions to a cell
ES2356342T3 (es) *	1998-01-05	2011-04-07	The University Of Washington	Mejora de transporte utilizando agentes de alteración de membrana.
US7098032B2 (en) *	2001-01-02	2006-08-29	Mirus Bio Corporation	Compositions and methods for drug delivery using pH sensitive molecules
US7033607B2 (en) *	1999-12-31	2006-04-25	Mirus Bio Corporation	pH-titratable polyampholytes for delivering polyions to a cell
AU2764801A (en) *	2000-01-07	2001-07-24	University Of Washington	Enhanced transport of agents using membrane disruptive agents
US20030134420A1 (en) *	2000-02-18	2003-07-17	Lollo Charles Peter	Methods and compositions for gene delivery
SE517421C2 (sv) *	2000-10-06	2002-06-04	Bioglan Ab	Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
US7094810B2 (en) *	2001-06-08	2006-08-22	Labopharm, Inc.	pH-sensitive block copolymers for pharmaceutical compositions
US6939564B2 (en) *	2001-06-08	2005-09-06	Labopharm, Inc.	Water-soluble stabilized self-assembled polyelectrolytes
US6780428B2 (en) *	2001-06-08	2004-08-24	Labopharm, Inc.	Unimolecular polymeric micelles with an ionizable inner core
EP1463518A2 (en) *	2001-12-28	2004-10-06	Supratek Pharma, Inc.	Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression
AU2003214387A1 (en) *	2002-03-07	2003-09-16	Biocompatibles Uk Limited	Drug carriers comprising amphiphilic block copolymers
AU2003293082A1 (en) *	2002-11-27	2004-06-23	Tufts University	Antioxidant-functionalized polymers
WO2004060977A1 (en) *	2002-12-30	2004-07-22	Nektar Therapeutics Al, Corporation	Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles
US7871818B2 (en) *	2003-01-31	2011-01-18	Roche Madison Inc.	Membrane active polymers
US7217776B1 (en) *	2003-02-14	2007-05-15	Iowa State University Research Foundation	pH-sensitive methacrylic copolymer gels and the production thereof
US20040162235A1 (en) *	2003-02-18	2004-08-19	Trubetskoy Vladimir S.	Delivery of siRNA to cells using polyampholytes
JP4535229B2 (ja) *	2003-05-08	2010-09-01	国立大学法人東京大学	ポリエチレングリコール−ポリカチオンブロック共重合体
US8821859B2 (en) *	2004-05-19	2014-09-02	Agency For Science, Technology And Research	Methods and articles for the delivery of therapeutic agents
US20060134221A1 (en) *	2004-12-03	2006-06-22	Vical Incorporated	Methods for producing block copolymer/amphiphilic particles
WO2006071769A1 (en) *	2004-12-28	2006-07-06	The Trustees Of The University Of Pennsylvania	Controlled release from block co-polymer worm micelles
US20060171980A1 (en) *	2005-02-01	2006-08-03	Helmus Michael N	Implantable or insertable medical devices having optimal surface energy
CN101155844A (zh) *	2005-03-31	2008-04-02	阿帕医药有限公司	聚乙二醇-聚缩醛和聚乙二醇-聚缩醛-聚原酸酯接枝共聚物和药物组合物
CN101203250B (zh) *	2005-04-15	2013-03-20	界面生物公司	经由非共价相互作用递送生物活性剂的方法、组合物及成形物件
US9139850B2 (en) *	2005-05-19	2015-09-22	L'oreal	Vectorization of dsRNA by cationic particles and topical use
US7718193B2 (en) *	2006-03-16	2010-05-18	University Of Washington	Temperature- and pH-responsive polymer compositions
US20080081075A1 (en) *	2006-10-02	2008-04-03	National Tsing Hua University	Multifunctional mixed micelle of graft and block copolymers and preparation thereof
US20080311045A1 (en) *	2007-06-06	2008-12-18	Biovaluation & Analysis, Inc.	Polymersomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
US20090036625A1 (en) *	2007-08-01	2009-02-05	Chung Yuan Christian University	Amphiphilic Polymer, Method for Forming the Same and Application thereof
US20100150952A1 (en) *	2008-11-07	2010-06-17	University Of Washington	pH-RESPONSIVE POLYMER CARRIER COMPOSITIONS FOR CYTOSOLIC PROTEIN DELIVERY

2009
- 2009-05-13 MX MX2010012237A patent/MX2010012237A/es active IP Right Grant
- 2009-05-13 AU AU2009246332A patent/AU2009246332A1/en not_active Abandoned
- 2009-05-13 US US12/992,541 patent/US20110142951A1/en not_active Abandoned
- 2009-05-13 EP EP09747515A patent/EP2296627A2/en not_active Withdrawn
- 2009-05-13 KR KR1020107027811A patent/KR20110020804A/ko not_active Withdrawn
- 2009-05-13 BR BRPI0911988A patent/BRPI0911988A2/pt not_active IP Right Cessation
- 2009-05-13 CA CA2724472A patent/CA2724472A1/en not_active Abandoned
- 2009-05-13 WO PCT/US2009/043853 patent/WO2009140432A2/en not_active Ceased
- 2009-05-13 CN CN200980122892XA patent/CN102076328A/zh active Pending
- 2009-05-13 JP JP2011509673A patent/JP2011520901A/ja not_active Withdrawn
2010
- 2010-11-10 IL IL209236A patent/IL209236A0/en unknown
- 2010-12-03 ZA ZA2010/08732A patent/ZA201008732B/en unknown

Also Published As

Publication number	Publication date
KR20110020804A (ko)	2011-03-03
CN102076328A (zh)	2011-05-25
AU2009246332A8 (en)	2011-01-13
JP2011520901A (ja)	2011-07-21
WO2009140432A2 (en)	2009-11-19
AU2009246332A1 (en)	2009-11-19
MX2010012237A (es)	2011-04-28
WO2009140432A3 (en)	2010-03-04
EP2296627A2 (en)	2011-03-23
CA2724472A1 (en)	2009-11-19
ZA201008732B (en)	2012-05-30
US20110142951A1 (en)	2011-06-16
IL209236A0 (en)	2011-01-31

Legal Events

Date	Code	Title	Description
2015-12-08	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.
2016-04-05	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
CY20222200002T2 (el)	2023-06-09	Βιοαποικοδομησιμα λιπιδια για την απελευθερωση δραστικων παραγοντων
BRPI0912252A2 (pt)	2017-06-13	dispositivos oftálmicos para liberação controlada de agentes ativos.
BRPI0817075A2 (pt)	2016-07-26	núcleos de fármaco para liberação prolongada de agentes terapêuticos
BRPI0909780A2 (pt)	2015-08-11	Composições e métodos para liberação de fármaco
BRPI0818874A2 (pt)	2015-05-05	Liberação de agentes ativos
ATE518527T1 (de)	2011-08-15	Rasagilinformulierung mit verzögerter freisetzung
BRPI0919466A2 (pt)	2015-12-01	composição farmacêutica para liberação modificada
BRPI0915885A2 (pt)	2015-11-03	micelas funcionais para a liberação direcionada de substâncias químicas em tecido duro
PT2355851T (pt)	2018-05-23	Novos lípidos e composições para a administração de agentes terapêuticos
BRPI0906391A2 (pt)	2015-07-07	Máscara higiênica para proteção de outros
BRPI0916931A2 (pt)	2015-11-24	agentes terapêuticos
UY33094A (es)	2011-07-29	Procedimiento para la preparacion de dronedarona
ZA201008732B (en)	2012-05-30	Micelles for intracellular delivery of therapeutic agents
DK2364293T3 (da)	2013-04-22	Hidtil ukendte pyrazol-4-N-alkoxycarboxamider som mikrobiocider
BR112012000687A2 (pt)	2016-02-16	tesoura para um endoscópio
BRPI0911714A2 (pt)	2016-08-09	acessório removível para calçado
BRPI1012638A2 (pt)	2016-04-05	métodos e intermediários para preparar agentes farmacêuticos
EP2484339A4 (en)	2015-02-11	Oil-in-water-type emulsion composition
BRPI0907651A2 (pt)	2015-07-21	Acessório para calçados
BRPI1011412A2 (pt)	2016-03-15	composição para liberação sustentada de droga compreendendo alutinante geopolimérico
BRPI1013079A2 (pt)	2017-06-06	hidrofobinas para dispersao de agentes ativos
BRPI0912428A2 (pt)	2016-02-16	formulação farmacêutica sólida de liberação retardada
BR112015008572A2 (pt)	2017-07-04	formulações de liberação modificada para oprozomib
BRPI0811732A2 (pt)	2014-11-18	Formulação de liberação prolongada de nevirapina
CO6960544A2 (es)	2014-05-30	Preparación de liberación sostenida